Aesica is planning to extend its presence in the animal health arena and hopes to significantly increase its business relating to this market by 2012.
Animal health products and treatments account for 2.5 per cent of the global pharmaceutical manufacturing market and Aesica is predicting significant annual growth across this niche market.*
Aesica is currently operating in this arena with a range of animal health products that are exclusively manufactured in the UK for a host of global customers. The company is now looking to build upon the successful delivery of these contracts and increase its share of the market both in the UK and the US.
Lal Khan, Business Unit Director, API, Aesica says: “It’s Aesica’s vision to become the leading supplier of APIs and formulated products to the global pharmaceutical and biotechnology industry and to achieve this target we must continually strive to extend and enhance our service offering. The animal health market presents a tangible opportunity for growth and we are keen to consolidate and build upon our existing portfolio of clients in this marketplace.
“Animal health is a key focus for the API business unit at Aesica, as we already have established assets and processes at our sites, as well as proven capability and expertise in delivering products and treatments for this market. As we are operating with a number of partners in the market it is a logical step for us to expand our portfolio and we are investing heavily in establishing Aesica as a leading provider in this field.”
The US commands the largest global share of the overarching pharmaceutical market, and it also currently dominates the animal health market. In response to the increased demand in this niche market and as part of its wider strategic global expansion, Aesica is investing heavily in developing its US portfolio.
Lal adds: “This year saw us expand fully into the US with the opening of two offices: New York and San Diego, the appointment of two new business development directors and further site expansion is planned to consolidate our offering. As a result, we are hoping to develop strong partnerships with specialty pharma and biotechnology organisations including those operating in the animal health arena.”
Aesica supplies contract development and contract manufacturing services for Active Pharmaceutical Ingredients and Formulated Products to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.
Its unique proposition lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within the company enables it to provide primary and secondary contract manufacturing services to the highest possible standards. It is this full-service offer and its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.
Aesica was founded in 2004 and has since more than trebled in size, from having a single API site in the North East of England to being a significant global player with multiple API and Formulations development and manufacturing sites in the UK, global offices in New York, San Diego and Shanghai and an international customer base.
* 2.5 per cent market share based upon figures published in 2004.